Navigation Links
ev3 Inc. Reports Third Quarter 2008 Financial Results
Date:10/31/2008

p> (Low) (High) (Low) (High)

Estimated net loss per

share $(0.05) $(0.03) $(0.48) $(0.46)

Amortization of

intangible assets 0.06 0.06 0.30 0.30

Stock-based

compensation 0.03 0.03 0.14 0.14

Intangible asset

impairment - - 0.10 0.10

Estimated non-GAAP

adjusted net

earnings per diluted

share 0.04 0.06 0.06 0.08

Estimated weighted

average diluted

shares outstanding 105,000,000 105,000,000 105,000,000 105,000,000

"Use and Economic Substance of Non-GAAP Financial Measures Used by ev3 and Usefulness of Such Non-GAAP Financial Measures to Investors

ev3 uses the non-GAAP financial measures described above as supplemental measures of performance and believes these measures facilitate operating performance comparisons from period to period and company to company by factoring out potential differences caused by acquisitions, dispositions, non- recurring, unusual or infrequent charges not related to ev3's regular, ongoing business, variations in capital structure, tax positions, depreciation, non- cash charges and certain large and unpredictable charges. ev3's management uses the non-GAAP financial measures used in this release to analyze the underlying trends in ev3's business, assess the performance of ev3's core operations, establish operational goals and forecasts that are used in allocating resources and evaluate ev3's performance period over period and in relation to its competitors' operating results. Additionally, ev3's management is evaluated on the basis of some of these non-GAAP financial measures when determining achievement of their incentive compensation performance targets.

ev3 believes t
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. eResearchTechnology Reports Third Quarter 2008 Results
2. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
4. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 The global ... of 22.3% during the forecast period of 2015 to ... increasingly being used in drug discovery and development process ... market growth. In addition to this,heavy investments by key ... applications are also propelling market growth. Browse 113 market ...
(Date:5/20/2015)... NEW YORK , May 20, 2015 /PRNewswire-USNewswire/ ... announced a leadership gift of $100 million from ... help create a new laboratory building that will ... campus extension. The Marie-Josée and Henry R. Kravis ... over the FDR Drive, spanning approximately three city ...
(Date:5/20/2015)... -- Resolution Bioscience announced today the successful results from their ... blood-based liquid biopsy for an ALK-gene fusion driver mutation ... common form of this cancer. Researchers or clinicians can ... therapies and direct them into clinical trials with a ... the CLIA authority in Washington State ...
Breaking Biology Technology:Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2
... Omthera Pharmaceuticals, Inc., a privately-held emerging ... of a randomized, open-label, four-way cross-over pharmacokinetics ... Omthera,s lead compound for the treatment of ... the leading prescription Omega-3.  Epanova is an ...
... Nov. 8, 2010 Solutia Inc. (NYSE: ... sold its Perkalink® business and entered into a ... to LANXESS, a Germany-based specialty chemicals company.   ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO) "The sale ...
... in Europe Could Be Prevented -- PRAGUE, November 8, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 2Solutia Announces Sale of Perkalink® Business and Select Primary Accelerators Assets 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 2Study Shows Cardiovascular Deaths in Europe Could Be Prevented 3Study Shows Cardiovascular Deaths in Europe Could Be Prevented 4Study Shows Cardiovascular Deaths in Europe Could Be Prevented 5Study Shows Cardiovascular Deaths in Europe Could Be Prevented 6Study Shows Cardiovascular Deaths in Europe Could Be Prevented 7Study Shows Cardiovascular Deaths in Europe Could Be Prevented 8Study Shows Cardiovascular Deaths in Europe Could Be Prevented 9Study Shows Cardiovascular Deaths in Europe Could Be Prevented 10
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Recognition Market by Solution (2D, 3D, Thermal, Emotion, Forensic), by ... End User (Government and Utilities, Consumer and Home) - ... Market to grow from $2.77 Billion in 2015 to ... Browse 79 market data Tables and ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/14/2015)... , May 14, 2015  Verificient Technologies, ... verification and online remote proctoring, announced a ... (SaaS) company and creator of the Canvas ... the two companies will benefit from the ... As a fully integrated multifactor ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... has bred more than 3,000 hybrid fish in his time ... Davis, a pursuit that has helped him create one of ... and demonstrated a key prediction in evolutionary biology. "We ... the evolution of new specialized species," said Martin, who with ...
... tracked electrical signals in the part of the brain linked to ... we know a room, we can go into it with our ... to the way we map out how to get from one ... location through increases in electrical activity, do not do so by ...
... of Philadelphia (CHOP) and BGI-Shenzhen today announced a ... sequencing and analysis of pediatric brain tumors, in ... (CBTTC). The research initiative will draw on the ... That center provides next-generation sequencing (NGS) under CAP/CLIA ...
Cached Biology News:A snapshot of pupfish evolution in action 2Rhythms in the brain help give a sense of location, study shows 2CHOP and BGI strengthen partnership with agreement on pediatric brain tumor collaboration 2
... called a ?cap? is present on ... mRNAs and many viral RNAs. Substitution ... of the GTP present in an ... the synthesis of transcripts with a ...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
Dedicated 29.5" X 18" platforms for Stackable shakers. These platforms are optimized for a particular flask clip size and are sold with a full load of flask clips....
Request Info...
Biology Products: